These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10941600)

  • 1. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate.
    Turay J; Grniaková V; Valka J
    Drugs Exp Clin Res; 2000; 26(3):83-8. PubMed ID: 10941600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
    Balogh Z; Seres I; Harangi M; Kovács P; Kakuk G; Paragh G
    Diabetes Metab; 2001 Nov; 27(5 Pt 1):604-10. PubMed ID: 11694861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid and apolipoproteins (ApoAI, ApoB, Apo CIII, ApoE) disturbance in hemodialysis (HD) and renal transplant (Tx) patients.
    Janicki K; Solski J; Janicka L; Kimak E; Bednarek-Skublewska A; Stettner S; Molas G
    Ann Univ Mariae Curie Sklodowska Med; 2004; 59(1):459-66. PubMed ID: 16146031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia.
    Kovács I; Toldy E; Abel T; Tarján J; Császár A
    Endothelium; 2005; 12(4):179-83. PubMed ID: 16162440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
    Yesilbursa D; Serdar A; Saltan Y; Serdar Z; Heper Y; Guclu S; Cordan J
    Kardiol Pol; 2005 Jun; 62(6):526-30. PubMed ID: 16123850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women.
    Fernandez ML; Metghalchi S; Vega-López S; Conde-Knape K; Lohman TG; Cordero-Macintyre ZR
    J Nutr Biochem; 2004 Dec; 15(12):717-21. PubMed ID: 15607644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder.
    Sarandol A; Sarandol E; Eker SS; Karaagac EU; Hizli BZ; Dirican M; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1103-8. PubMed ID: 16716479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study.
    Holme I; Høstmark AT; Anderssen SA
    J Intern Med; 2007 Aug; 262(2):235-43. PubMed ID: 17645591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
    Roglans N; Bellido A; Rodríguez C; Cabrero A; Novell F; Ros E; Zambón D; Laguna JC
    Clin Pharmacol Ther; 2002 Dec; 72(6):692-701. PubMed ID: 12496750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.
    Zambon A; Brown BG; Deeb SS; Brunzell JD
    J Intern Med; 2006 May; 259(5):473-80. PubMed ID: 16629853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E.
    Fu T; Kashireddy P; Borensztajn J
    Biochem J; 2003 Aug; 373(Pt 3):941-7. PubMed ID: 12713444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients.
    Ghorbanihaghjo A; Argani H; Rahbaninoubar M; Rashtchizadeh N
    Clin Biochem; 2005 Dec; 38(12):1076-80. PubMed ID: 16153628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term treatment of hyperlipoproteinemia with etofibrate].
    Bartz VT; Gatz J; Slotty C; Schröter C; Töle R; Wand P
    Fortschr Med; 1993 Sep; 111(25):398-400. PubMed ID: 8406286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations of apolipoproteins in patients with thyroid dysfunction.
    Tada H; Irie Y; Yagoro A; Ohya H; Hayashi S; Fushimi R; Tamaki H; Amino N
    Thyroidology; 1994 Dec; 6(3):93-7. PubMed ID: 7545001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
    Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.